Company intelligence / Profile preview
New G Lab
Seoul, South Koreanewglabpharma.com ↗
- Ownership
- Public · GLAB
- Development stage
- Other
01
Overview
New G Lab Pharma is a South Korean biopharmaceutical company focused on developing metabolic anticancer therapies. The company's lead candidate, KAT-001, is a formulation of 2-deoxy-D-glucose (2-DG) designed to inhibit hexokinase 2 and disrupt the glycolytic pathway in cancer cells, leveraging the Warburg effect. Beyond oncology, the company has explored applications for its metabolic inhibitors in viral infections and other metabolic disorders. New G Lab Pharma operates through its headquarters in Korea and a research-focused subsidiary in the United States. The company's approach aims to selectively target malignant cells while sparing healthy tissue by interfering with cancer-specific energy production.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on New G Lab.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on New G Lab.